Opdivo (nivolumab)
pCPA File Number:
22041
Negotiation Status:
Concluded with an LOI
Indication(s):
Urothelial carcinoma (UC), monotherapy for the adjuvant treatment of adult patients who are at high risk of recurrence after undergoing radical resection of UC
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PC0272-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: